Zidovudine at the concentration from 2 to 100 μM can activate UGT2B7 in human liver carcinoma cell line (HepG2), in contrast, it showed a downtrend from 50 to 2500 μM in human thyroid carcinoma cell (THLE2) (Fang et al., 2014). Here, UGT2B7 is linked to thyroid gland carcinoma.